Jennifer Rhodes is a partner in Ice Miller's Private Equity/Venture Services Practice. Her primary area of concentration is in private equity fund formation and operations, venture capital and private equity financings, mergers and acquisitions, and general corporate matters.
In our third in a series of life science distinguished speakers luncheons we were honored to have Dr. Ora Hirsch Pescovitz the Executive Associate Dean for Research and Edwin Letzter Professor of Pediatrics at Indiana University School of Medicine. She served as director of Pediatric Endocrinology and Diabetology at Indiana University School of Medicine from 1990-2004. In September 2004, she was named to the position of CEO and President of Riley Children's Hospital. In her role in the Dean's office, she oversees all research at the School of Medicine
Dr. Pescovitz asked the question why do life science research in Indiana? And the answer lies within the state’s national ranking for five major health indicators in Indiana: cancer deaths, smoking prevalence, obesity, cardiovascular deaths, and diabetes. The state ranks in the bottom half of each of these health indicators, and in the bottom 10 of all states in most cases.
Not only the health impact, but the economic impact is another reason for the state to focus on the life science industry. Dr. Pescovitz mentioned that high-tech research driven industries have contributed to over a third of the nation's economic growth over the past decade and the U.S. biotech industry had revenues of over $65 billion in 2007, which is up 11% nationally over 2006, so why shouldn't Indiana be getting a piece of that important pie?
Dr. Pescovitz also discussed how Indiana University School of Medicine is driving the life sciences initiative in Indiana and provided examples of new Indiana businesses, such as Fast Diagnostics, CS Keys, EndGenitor and Immuneworks, not only expanding the technology and research but also bringing in new forms of revenue to the State. She pointed out that success in the life sciences industry requires a significant amount of collaboration.
The Indiana Clinical and Translation Scientists Institute is a statewide partnership to transform life science research and health care delivery. The goals of this project are largely to use basic discoveries and translational approaches to new scientific discoveries from the bench to the bed-side and then to translate these discoveries from the bed-side and move them into the community and from the community into actual medical practice and then taking that feedback from the community back to the researchers so it really is a full cycle.
Dr. Pescovitz closed by commenting that the cost of life science research is high, but the return on investment is priceless.
In our third in a series of life science distinguished speakers luncheons we were honored to have Dr. Ora Hirsch Pescovitz the Executive Associate Dean for Research and Edwin Letzter Professor of Pediatrics at Indiana University School of Medicine. She served as director of Pediatric Endocrinology and Diabetology at Indiana University School of Medicine from 1990-2004. In September 2004, she was named to the position of CEO and President of Riley Children's Hospital. In her role in the Dean's office, she oversees all research at the School of Medicine
Dr. Pescovitz asked the question why do life science research in Indiana? And the answer lies within the state’s national ranking for five major health indicators in Indiana: cancer deaths, smoking prevalence, obesity, cardiovascular deaths, and diabetes. The state ranks in the bottom half of each of these health indicators, and in the bottom 10 of all states in most cases.
Not only the health impact, but the economic impact is another reason for the state to focus on the life science industry. Dr. Pescovitz mentioned that high-tech research driven industries have contributed to over a third of the nation's economic growth over the past decade and the U.S. biotech industry had revenues of over $65 billion in 2007, which is up 11% nationally over 2006, so why shouldn't Indiana be getting a piece of that important pie?
Dr. Pescovitz also discussed how Indiana University School of Medicine is driving the life sciences initiative in Indiana and provided examples of new Indiana businesses, such as Fast Diagnostics, CS Keys, EndGenitor and Immuneworks, not only expanding the technology and research but also bringing in new forms of revenue to the State. She pointed out that success in the life sciences industry requires a significant amount of collaboration.
The Indiana Clinical and Translation Scientists Institute is a statewide partnership to transform life science research and health care delivery. The goals of this project are largely to use basic discoveries and translational approaches to new scientific discoveries from the bench to the bed-side and then to translate these discoveries from the bed-side and move them into the community and from the community into actual medical practice and then taking that feedback from the community back to the researchers so it really is a full cycle.
Dr. Pescovitz closed by commenting that the cost of life science research is high, but the return on investment is priceless.
Powered by Compendium
Comments for September's Distinguished Speaker Series -- Comments by Jennifer Rhodes